BeiGene eyes $933m in latest HK biotech offering
BeiGene is set to become the first issuer to sell shares under new rules in Hong Kong, after the exchange moved to encourage secondary listings by overseas-traded companies.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: